Conditions: Alzheimer's Disease
Keywords: Delirium Dementia Amnestic Cognitive Disorders Mental Disorders Nervous System Diseases Central Nervous System Diseases
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 5
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the long-term safety and tolerability of dimebon in subjects with moderate-to-severe Alzheimer's Disease.

Detailed description:
This study was terminated on May 7, 2010 due to modification of the dimebon development plan, following the lack of demonstration of efficacy in the completed DIM14 (CONNECTION) Study. The study was not terminated due to any safety findings. Dimebon has been well-tolerated in clinical trials. Demonstration of efficacy for dimebon in Alzheimer's disease is pending completion of the ongoing DIM18 (CONCERT) Study.

Arms:
arm 1: None

Interventions: intervention 1: Dimebon tablet for oral administration
Intervention descriptions: intervention 1: 10 mg TID for Week 1, followed by 20 mg TID for remainder of study

Protocol document: